MLi-2

Name: MLi-2
Brand: MedChemExpress
SKU: HY-100411
Rating: 5.0 (12 reviews)

Cat. No.: HY-100411 Purity: 99.50%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

MLi-2, a chemical probe, is an orally active and highly selective LRRK2 inhibitor with an IC₅₀ of 0.76 nM. MLi-2 has the potential for Parkinson’s disease.

For research use only. We do not sell to patients.

CAS No. : 1627091-47-7

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
1 mg	In-stock	Estimated Time of Arrival: December 31
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	Get quote
500 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 12 publication(s) in Google Scholar

Other Forms of MLi-2:

MLi-2 (Standard) Get quote

12 Publications Citing Use of MCE MLi-2

In Vivo Efficacy Study

Flow Cytometry

Cell Imaging/Staining

: MLi-2 purchased from MedChemExpress. Usage Cited in: J Cell Biol. 2025 Nov 3;224(11):e202404018. [Abstract]; U2OS cells were transfected with HaloTag-LRRK2 for 36 h. Cells were then treated with DMSO, LLOME (1 mM), or LLOME+MLi2 (1 μM, 90 min prior to LLOME incubation) for 2 h before fixation. Cells were then stained for RILPL1 and LAMP2.

: MLi-2 purchased from MedChemExpress. Usage Cited in: J Cell Biol. 2025 Nov 3;224(11):e202404018. [Abstract]; Quantification of the RILPL1 lysosomes per cell in the three different conditions. Cells were then treated with DMSO, LLOME (1 mM), or LLOME+MLi2 (1 μM, 90 min prior to LLOME incubation) for 2 h.

: MLi-2 purchased from MedChemExpress. Usage Cited in: J Cell Biol. 2025 Nov 3;224(11):e202404018. [Abstract]; HEK293T cells stably expressing GFP-LRRK2 and TMEM192-3xHA were seeded and treated with DMSO, LLOME (1 mM), or LLOME + MLi2 (1 μM, 90 min prior to LLOME incubation) 24 h later. Lysosomes were purified with anti-HA beads following the LYSO-IP technique. Lysosomes were then lysed, and their content was analyzed via immunoblotting.

: MLi-2 purchased from MedChemExpress. Usage Cited in: Acta Neuropathol. 2023 Aug;146(2):245-261. [Abstract]; Disease index score evaluation in WT and GS mice treated with placebo or MLi-2 (25 mg/kg/d in diet), after DSS administration.

: MLi-2 purchased from MedChemExpress. Usage Cited in: Acta Neuropathol. 2023 Aug;146(2):245-261. [Abstract]; Colonic immunophenotyping by fow cytometry of GS mice treated with MLi-2 (25 mg/kg/d in diet) or placebo, as well as WT mice, after DSS administration.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description

MLi-2, a chemical probe, is an orally active and highly selective LRRK2 inhibitor with an IC₅₀ of 0.76 nM. MLi-2 has the potential for Parkinson’s disease^[1].

IC₅₀ & Target

IC50: 0.76 nM (LRRK2)^[1]

In Vitro

MLi-2 exhibits exceptional potency in a purified LRRK2 kinase assay in vitro( IC₅₀=0.76 nM), a cellular assay monitoring dephosphorylation of LRRK2 pSer935 LRRK2 (IC₅₀=1.4 nM), and a radioligand competition binding assay (IC₅₀=3.4 nM). MLi-2 has greater than 295-fold selectivity for over 300 kinases in addition to a diverse panel of receptors and ion channels^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Acute oral and subchronic dosing in MLi-2 mice results in dose-dependent central and peripheral target inhibition over a 24-hour period as measured by dephosphorylation of pSer935 LRRK2. Treatment of MitoPark mice with MLi-2 is well tolerated over a 15-week period at brain and plasma exposures. Morphologic changes in the lung, consistent with enlarged type II pneumocytes, are observed in MLi-2-treated MitoPark mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

379.46

Formula

C₂₁H₂₅N₅O₂

CAS No.

1627091-47-7

Appearance

Solid

Color

White to off-white

SMILES

C[C@@](C1)([H])O[C@](C)([H])CN1C2=CC(C3=NNC4=CC=C(OC5(C)CC5)C=C43)=NC=N2

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL (131.77 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.6353 mL	13.1766 mL	26.3532 mL
5 mM	0.5271 mL	2.6353 mL	5.2706 mL
10 mM	0.2635 mL	1.3177 mL	2.6353 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 5% DMSO 40% PEG300 5% Tween-80 50% Saline
Solubility: 2.87 mg/mL (7.56 mM); Suspended solution; Need ultrasonic
Protocol 2

Add each solvent one by one: 5% DMSO 95% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.87 mg/mL (7.56 mM); Clear solution
Protocol 3

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2 mg/mL (5.27 mM); Clear solution

This protocol yields a clear solution of ≥ 2 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 4

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2 mg/mL (5.27 mM); Clear solution

This protocol yields a clear solution of ≥ 2 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.0 mg/mL) to 900 μL Corn oil, and mix evenly.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 30% SBE-β-CD in Saline
Solubility: 5 mg/mL (13.18 mM); Suspension solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.80%

Select Batch:

Data Sheet (277 KB) SDS (393 KB)

COA (252 KB) LCMS (265 KB)

Handling Instructions (2659 KB)

References

[1]. Fell MJ, et al. MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition. J Pharmacol Exp Ther. 2015 Dec;355(3):397-409. [Content Brief]

Animal Administration
^[1]

Mice: MLi-2 is suspended in 30% Captisol and administered in a volume of 10 mL/kg. Dose calculations are on the basis of active moiety. Mice receive MLi-2 [1-100 mg/kg; by mouth (PO)], or vehicle 1 hour prior to euthanasia by excess CO2. Immediately following euthanasia, mouse brain cortex is dissected and frozen on a steel plate over dry ice for analysis of pSer935 LRRK2 via Western Blot. Plasma and brain samples are collected and frozen for determination of MLi-2 levels by LC-MS/MS^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

References

[1]. Fell MJ, et al. MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition. J Pharmacol Exp Ther. 2015 Dec;355(3):397-409. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.6353 mL	13.1766 mL	26.3532 mL	65.8831 mL
	5 mM	0.5271 mL	2.6353 mL	5.2706 mL	13.1766 mL
	10 mM	0.2635 mL	1.3177 mL	2.6353 mL	6.5883 mL
	15 mM	0.1757 mL	0.8784 mL	1.7569 mL	4.3922 mL
	20 mM	0.1318 mL	0.6588 mL	1.3177 mL	3.2942 mL
	25 mM	0.1054 mL	0.5271 mL	1.0541 mL	2.6353 mL
	30 mM	0.0878 mL	0.4392 mL	0.8784 mL	2.1961 mL
	40 mM	0.0659 mL	0.3294 mL	0.6588 mL	1.6471 mL
	50 mM	0.0527 mL	0.2635 mL	0.5271 mL	1.3177 mL
	60 mM	0.0439 mL	0.2196 mL	0.4392 mL	1.0981 mL
	80 mM	0.0329 mL	0.1647 mL	0.3294 mL	0.8235 mL
	100 mM	0.0264 mL	0.1318 mL	0.2635 mL	0.6588 mL

MLi-2 Related Classifications

Neurological Disease

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

MLi-21627091-47-7MLi2MLi 2LRRK2Leucine-rich repeat kinase 2orallyParkinson’sdiseaseInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

MLi-2

Customer Review

Other Forms of MLi-2:

MLi-2 Related Antibodies

12 Publications Citing Use of MCE MLi-2

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity

Protocol

Purity & Documentation

References

Customer Review

MLi-2 Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

MLi-2 Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report